N/A
N=48
Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis
Rheumatoid Arthritis
Bottom Line
View on ClinicalTrials.gov: NCT02368093 ↗Enrolled (actual)
48
Serious AEs
—
Results posted
Mar 2015
Primary outcome: Primary: Good European League Against Rheumatism (EULAR) Therapeutic Response Rate — 6; 4 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Dextromethorphan hydrobromide (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Taichung Veterans General Hospital
- Primary completion
- Sep 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Good European League Against Rheumatism (EULAR) Therapeutic Response Rate |
6; 4 | — |
Summary
Rheumatoid arthritis were randomized to a 6-month treatment of oral dextromethorphan hydrobromide or placebo as an add-on therapy to traditional disease-modifying anti-rheumatic drugs (DMARDs). Disease activity were assessed.
Eligibility Criteria
Inclusion Criteria
- Patients fulfilling the 2010 criteria of the American College of Rheumatology (ACR) for RA
Exclusion Criteria
- Receive biological therapy for RA, including Etanercept, Adalimumab, Golimumab, Tocilizumab, Rituximab, Abatacept.
Data sourced from ClinicalTrials.gov (NCT02368093). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.